Clinical Trials Logo

Filter by:
NCT ID: NCT05433896 Completed - Pharmacokinetics Clinical Trials

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Start date: November 1, 2020
Phase: Phase 1
Study type: Interventional

In this open label, single-sequence study, subjects received one dose of XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation at the start of study on Day 1 and Day 6. Omeprazole 40 mg was administered on Day 2, 3, 4, 5 and 6. The study was conducted in two groups.

NCT ID: NCT05433571 Completed - Visual Acuity Clinical Trials

Evaluation of Rotation With a Multifocal Toric Contact Lens

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

The study is a bilateral, single-masked, single-visit, non-dispensing 2x2 crossover study to confirm a finalized design of a prototype contact lens. There will be eight study lens types, however, each subject will only be randomized to receive two study lens types.

NCT ID: NCT05433519 Completed - Pregnancy Related Clinical Trials

Diagnostic Accuracy of a Novel Machine Learning Algorithm to Estimate Gestational Age

Start date: July 27, 2022
Phase:
Study type: Observational

This is a prospective cohort study of women enrolled early in pregnancy, with randomization to determine the timing of three follow-up visits in the second and third trimester. At each of these follow-up visits, investigators will assess gestational age with the FAMLI technology and compare that estimate to the known gestational age established early in pregnancy.

NCT ID: NCT05433506 Completed - Obese Clinical Trials

Safety and Pharmacokinetics of HU6

Start date: September 15, 2022
Phase: Phase 1
Study type: Interventional

Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as the tablet formulation. Eight subjects will be enrolled to participate in all of the ascending study periods.

NCT ID: NCT05433233 Completed - Hypertension Clinical Trials

Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension

Start date: September 9, 2020
Phase: N/A
Study type: Interventional

Eight out of ten older adults have hypertension in the US, which is a strong risk factor for cardiovascular events. To manage hypertension, regular and structured exercise is effective and strongly recommended regardless of drug therapy. However, structured exercise is often performed in a health club, could be difficult, and warrants caution in older adults with chronic conditions. In contrast, the most common lifestyle physical activity in older adults is walking, which is inexpensive, easy, and safe. Recent technological advancement in activity monitoring provides reliable step counts and promotes lifestyle walking. Although one of the most popular public health goals is walking 10,000 steps/day, recent studies found that it is unrealistic and difficult to achieve. Further, there is very little evidence whether walking 10,000 steps/day is effective, specifically in older adults with hypertension. Walking 3,000 extra steps/day 5 days/week is equivalent to meeting the current aerobic physical activity guidelines, as it takes about 30 minutes each day, and is more realistic and achievable. Steps/day is easy to understand and captures most physical activities in older adults. However, there are no specific guidelines about how many daily steps are needed for older adults in the current physical activity guidelines. Thus, this project is aimed to provide pilot data to answer a simple, but unknown, question about physical activity in older adults: "Can increasing lifestyle walking in older adults with hypertension reduce blood pressure? And can older adults maintain a lifestyle walking intervention on their own?". This project will significantly contribute to developing more effective and easy physical activity guidelines for older adults.

NCT ID: NCT05432986 Completed - Hydrocephalus Clinical Trials

Assessment of CSF Shunt Flow With Thermal Measurements B

STEALTH
Start date: July 7, 2022
Phase:
Study type: Observational

This study evaluates the performance of a non-invasive thermal measurement device for assessing CSF shunt flow. Patients with an existing implanted shunt and symptoms of shunt malfunction will be evaluated with the study device.

NCT ID: NCT05432752 Completed - Brain Concussion Clinical Trials

Concussion Pen Screening Tool

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

To compare the use of the Concussion Pen to current clinical care practice. This will be a prospective study of a maximum of 24 subjects, with a goal enrollment of 20 subjects (10 in each cohort). All subjects will undergo clinical evaluation for concussion and will also be evaluated using the Concussion Pen. Randomization to being evaluated using clinical care first then the Concussion Pen and vice versa will be utilized. This randomization will help to control for evaluation fatigue on the part of study participants.

NCT ID: NCT05432674 Completed - Fall Clinical Trials

Digital Fall Prevention Study

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The Digital Fall Prevention Study is a single-group unblinded study to explore the feasibility and acceptability of a 3-month fall prevention exercise program delivered digitally via a tablet interface. Evidence-based exercise programs and motivational techniques will be used along with new wearable technology to predict fall risk.

NCT ID: NCT05432622 Completed - Melanoma Clinical Trials

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Start date: December 19, 2019
Phase:
Study type: Observational

The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.

NCT ID: NCT05432596 Completed - Atopic Dermatitis Clinical Trials

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Start date: May 11, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.